Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | GC | P02774 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | RXRA | P19793 | 1/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.74 |
| ▸ | CNR1 | P21554 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | HTR2C | P28335 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.74 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14489107 | 1.00 | VDR (1.00) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL3056435 | 1.00 | VDR (1.00) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL13996344 | 1.00 | VDR (1.00) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL19988205 | 1.00 | VDR (1.00) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL26322255 | 0.94 | VDR (0.88) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL26322289 | 0.94 | VDR (0.88) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL3177008 | 0.91 | VDR (0.84) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL13392705 | 0.91 | VDR (0.84) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL13392172 | 0.91 | VDR (0.84) | VDRMAPTNR1I2ABCB11GC | |
| SCHEMBL10307541 | 0.90 | VDR (0.82) | VDRMAPTNR1I2ABCB11GC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041663-A1 | PREVENTION OF ROSACEA INFLAMMATION | UNIV CALIFORNIA (US) | 2026-02-12 | — | — | US | claimed |
| US-20230181518-A1 | PREVENTION OF ROSACEA INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-15 | — | — | US | claimed |
| US-20260041663-A1 | PREVENTION OF ROSACEA INFLAMMATION | UNIV CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| US-12285404-B2 | Prevention of rosacea inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-29 | — | — | US | disclosed |
| EP-3603646-B1 | VITAMIN D3 AND ANALOGS THEREOF FOR TREATING ALOPECIA | BPGBIO INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11903952-B2 | Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection | NORTHWESTERN UNIVERSITY (US) | 2024-02-20 | — | — | US | disclosed |
| EP-3003497-B1 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | BPGBIO INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230302022-A1 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | BERG SURVIVOR’S TRUST | 2023-09-28 | — | — | US | disclosed |
| US-20230181518-A1 | PREVENTION OF ROSACEA INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-15 | — | — | US | disclosed |
| US-20220362273-A1 | COMBINATION THERAPY FOR TREATING OR PREVENTING SKIN DAMAGE | CASE WESTERN RESERVE UNIVERSITY | 2022-11-17 | — | — | US | disclosed |
| US-11382890-B2 | Prevention of rosacea inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-12 | — | — | US | disclosed |
| US-11305016-B2 | Vitamin D3 and analogs thereof for treating alopecia | BERG LLC (US) | 2022-04-19 | — | — | US | disclosed |
| US-9221753-B2 | Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-12-29 | — | — | US | disclosed |
| US-9221753-B2 | Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-12-29 | — | — | US | disclosed |
| US-20110319644-A1 | PROCESS FOR PRODUCTION OF 1-HYDROXY-19-NORCYCLOVITAMIN D DERIVATIVE AND INTERMEDIATE FOR THE PRODUCTION | MERCIAN CORPORATION (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20070135394-A1 | Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319644-A1 | PROCESS FOR PRODUCTION OF 1-HYDROXY-19-NORCYCLOVITAMIN D DERIVATIVE AND INTERMEDIATE FOR THE PRODUCTION | CYP24A1, CYP27B1, CYP2R1 | VDR 4/4885MAPT 2485/4885NR1I2 1375/4885 |
| US-20230302022-A1 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | CYP24A1, CYP2R1, VDR | VDR 3/4885MAPT 3777/4885NR1I2 2459/4885 |
| US-11305016-B2 | Vitamin D3 and analogs thereof for treating alopecia | CYP24A1, VDR, CYP2R1 | VDR 2/4885MAPT 4027/4885NR1I2 1373/4885 |
| US-20070135394-A1 | Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds | CYP24A1, CYP2R1, VDR | VDR 3/4885MAPT 1284/4885NR1I2 3727/4885 |
| US-11903952-B2 | Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection | VDR, CYP24A1, GC | VDR 1/4885MAPT 3896/4885NR1I2 1553/4885 |
| US-20260041663-A1 | PREVENTION OF ROSACEA INFLAMMATION | CPA3, CTSD, TPSD1 | VDR 8/4885MAPT 1379/4885NR1I2 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.